ReviewMolecules (Basel, Switzerland)2019
Antiviral Activities of Silymarin and Derivatives.
Review in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04394208 (Trial of Silymarin in Adults With COVID-19 Pneumonia), which is not on this map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Trial of Silymarin in Adults With COVID-19 Pneumonia
Who cites it
41 citing papers in PubMed.
- Hepatitis C Virus and Type 2 Diabetes: Mechanisms, Clinical Impact, and Post-DAA Management.Journal of medical virology · 2026Review
- Review
- Article
- Silymarin and Silybin: Rejuvenating Traditional Remedies with Modern Delivery Strategies.Pharmaceutics · 2025Review
- Review
- Differential tropisms of old and new world hantaviruses influence virulence and developing host-directed antiviral candidates.PLoS pathogens · 2025Article
- Effects and Mechanisms of Silibinin on Influenza A/H1N1 Pathogenesis in a Mouse Model.Journal of tropical medicine · 2025Article
- Silibinin-Loaded Liposomes: The Influence of Modifications on Physicochemical Characteristics, Stability, and Bioactivity Associated with Dermal Application.Pharmaceutics · 2024Article
- Liposome Encapsulation Enhances the Antidiabetic Efficacy of Silibinin.Pharmaceutics · 2024Article
- Mini-encyclopedia of mitochondria-relevant nutraceuticals protecting health in primary and secondary care-clinically relevant 3PM innovation.The EPMA journal · 2024Article
- Insights into the Management of Chronic Hepatitis in Children-From Oxidative Stress to Antioxidant Therapy.International journal of molecular sciences · 2024Review
- Metabolic profiling of milk thistle different organs using UPLC-TQD-MS/MS coupled to multivariate analysis in relation to their selective antiviral potential.BMC complementary medicine and therapies · 2024Article
- Review
- Anti-Viral Activity of Bioactive Molecules of Silymarin against COVID-19 via In Silico Studies.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Nutraceuticals and Their Contribution to Preventing Noncommunicable Diseases.Foods (Basel, Switzerland) · 2023Review
- Microbially produced vitamin B12 contributes to the lipid-lowering effect of silymarin.Nature communications · 2023Article
- Effect of Structural Differences in Naringenin, Prenylated Naringenin, and Their Derivatives on the Anti-Influenza Virus Activity and Cellular Uptake of Their Flavanones.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Simultaneous Determination of Glibenclamide and Silymarin Released from Chitosan Microparticles by HPLC-ESI-MS Technique: Method Development and Validation.Pharmaceutics · 2022Article
- The favorable impacts of silibinin polyphenols as adjunctive therapy in reducing the complications of COVID-19: A review of research evidence and underlying mechanisms.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Phytosomes as a Plausible Nano-Delivery System for Enhanced Oral Bioavailability and Improved Hepatoprotective Activity of Silymarin.Pharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Silymarin flavonolignans are well-known agents that typically possess antioxidative, anti-inflammatory, and hepatoprotective functions. Recent studies have also documented the antiviral activities of silymarin and its derivatives against several viruses, including the flaviviruses (hepatitis C virus and dengue virus), togaviruses (Chikungunya virus and Mayaro virus), influenza virus, human immunodeficiency virus, and hepatitis B virus. This review will describe some of the latest preclinical and clinical studies detailing the antiviral profiles of silymarin and its derivatives, and discuss their relevance for antiviral drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.